Progress in research of antiphospholipid antibodies in preeclampsia

doi:10.3877/cma.j.issn.1674-0785.2020.02.013

Abstract

Abstract:

Antiphospholipid antibodies are a class of autoimmune antibodies that bind to phospholipids or phospholipid-binding proteins and are closely related to thrombosis and poor maternal history. Patients with high levels of antiphospholipid antibodies are prone to adverse pregnancy outcomes such as preeclampsia. Preeclampsia occurs in pregnancy and can cause multiple organ damage with severe life-threatening complications in the mother and child. The pathogenesis of preeclampsia is still not clear. Studies suggest that antiphospholipid antibodies may participate in the pathogenesis of preeclampsia by inducing oxidative stress and promoting intravascular inflammation. Early detection and early intervention for patients with antiphospholipid antibodies are essential for achieving a good pregnancy outcome.

Key words: Antiphospholipid antibody, Preeclampsia, Neutrophil extracellular traps, Oxidative stress, Genomics, MicroRNA

Chenlu Zhang, Min Jiang, Jianying Luo. Progress in research of antiphospholipid antibodies in preeclampsia[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(02): 140-143.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2020.02.013

https://zhlcyszz.cma-cmc.com.cn/EN/Y2020/V14/I02/140

References 39

[1]	Gibbins KJ, Tebo AE, Nielsen SK, et al. Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study [J]. Lupus, 2018, 27(12): 1903-1910.
[2]	Heydarlou H, Eghabl-Fard S, Ahmadi M, et al. Investigation of follicular helper T cells, as a novel player, in preeclampsia [J]. J Cell Biochem, 2019, 120(3): 3845-3852.
[3]	Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology [J]. Nat Rev Nephrol, 2014, 10(8): 466-480.
[4]	谢幸，孔北华，段涛, 等. 妇产科学 [M]. 9版. 北京: 人民卫生出版社, 2018: 83-91.
[5]	Truong G, Guanzon D, Kinhal V, et al. Oxygen tension regulates the miRNA profile and bioactivity of exosomes released from extravillous trophoblast cells - Liquid biopsies for monitoring complications of pregnancy [J]. PLoS One, 2017, 12(3): e0174514.
[6]	Tong M, Johansson C, Xiao F, et al. Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia [J]. Sci Rep, 2017, 7(1): 16556.
[7]	Craici IM, Wagner SJ, Weissgerber TL, et al. Advances in the pathophysiology of pre-eclampsia and related podocyte injury [J]. Kidney Int, 2014, 86(2): 275-285.
[8]	Matsubara K, Higaki T, Matsubara Y, et al. Nitric Oxide and Reactive Oxygen Species in the Pathogenesis of Preeclampsia [J]. Int J Mol Sci, 2015, 16(3): 4600-4614.
[9]	Adu-Bonsaffoh K, Antwi DA, Gyan B, et al. Endothelial dysfunction in the pathogenesis of pre-eclampsia in Ghanaian women [J]. BMC Physiol, 2017, 17(1): 5.
[10]	Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia [J]. Nat Med, 2006, 12(6): 642-649.
[11]	Zeisler H, Llurba E, Chantraine FJ, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting [J]. Ultrasound Obstet Gynecol, 2019, 53(3): 367-375.
[12]	Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study [J]. Am J Obstet Gynecol, 2016, 214(1): 108.e1-108.e14.
[13]	Mineo C. Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis [J]. Curr Rheumatol Rep, 2013, 15(5): 324.
[14]	McCarthy FP, Kingdom JC, Kenny LC, et al. Animal models of preeclampsia; uses and limitations [J]. Placenta, 2011, 32(6): 413-419.
[15]	Erpenbeck L, Chowdhury CS, Zsengeller ZK, et al. PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model [J]. Biol Reprod, 2016, 95(6): 132.
[16]	Giaglis S, Stoikou M, Grimolizzi F, et al. Neutrophil migration into the placenta: Good, bad or deadly? [J]. Cell Adhesion & Migration, 2016, 10(1-2): 208-225.
[17]	Lip SV, Boekschoten MV, Hooiveld GJ, et al. Early-onset preeclampsia, plasma microRNAs and endothelial cell function [J]. Am J Obstet Gynecol, 2019, 12(2): 98-106.
[18]	Perez-Sanchez C, Arias-de la Rosa I, Aguirre MA, et al. Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome [J]. Haematologica, 2018, 103(5): 908-918.
[19]	Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results [J]. Lupus science & medicine, 2016, 3(1): e000131.
[20]	Lazzaroni MG, Andreoli L, Chighizola CB, et al. Risk factors for adverse pregnancy outcome in antiphospholipid antibodies carriers: Results from a multicenter italian cohort over 20 years of experience [J]. Ann Rheum Dis, 2017, 76(70): 1-70.
[21]	Do Prado AD, Piovesan DM, Staub HL, et al. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis [J]. Obstet Gynecol, 2010, 116(6): 1433-1443.
[22]	Ferrer-Oliveras R, Llurba E, Cabero-Roura L, et al. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets [J]. Lupus, 2012, 21(3): 257-263.
[23]	Ding X, Yang Z, Han Y, et al. Long-chain fatty acid oxidation changes in a beta2 glycoprotein I-induced preeclampsia-like mouse model [J]. Placenta, 2014, 35(6): 392-397.
[24]	Skeith L, Abou-Nassar KE, Walker M, et al. Are Anti-2 Glycoprotein 1 Antibodies Associated with Placenta-Mediated Pregnancy Complications? A Nested Case-Control Study [J]. Am J Perinatol, 2018, 35(11): 1093-1099.
[25]	张文. 抗磷脂综合征治疗进展 [J]. 中国实用内科杂志, 2017, 37(2): 120-123.
[26]	Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia [J]. N Engl J Med, 2017, 377(7): 613-622.
[27]	Rolnik DL, O′Gorman N, Roberge S, et al. Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation [J]. Ultrasound Obstet Gynecol, 2017, 50(5): 551-556.
[28]	Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis [J]. Am J Obstet Gynecol, 2017, 216(2): 110-20. e6.
[29]	马晓彬. 低剂量阿司匹林预防高危孕妇子病前期的临床价值 [J]. 中国医药指南, 2019, 17(7): 79-80.
[30]	McLaughlin K, Baczyk D, Potts A, et al. Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia [J]. Hypertension, 2017, 69(1): 180-188.
[31]	Roberge S, Demers S, Nicolaides KH, et al. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis [J]. Ultrasound Obstet Gynecol, 2016, 47(5): 548-553.
[32]	Lecarpentier E, Gris JC, Cochery-Nouvellon E, et al. Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis [J]. Obstet Gynecol, 2018, 131(1): 63-69.
[33]	Van Hoorn ME, Hague WM, van Pampus MG, et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT [J]. Eur J Obstet Gynecol Reprod Biol, 2016, 197: 168-173.
[34]	Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial [J]. Am J Obstet Gynecol, 2017, 216(3): 296. e1-e14.
[35]	Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases [J]. Autoimmun Rev, 2019, 18(4): 406-414.
[36]	Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies [J]. Semin Thromb Hemost, 2017, 43(6): 562-571.
[37]	Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy [J]. J Clin Invest, 2016, 126(8): 2933-2940.
[38]	Xu J, Jia X, Gu Y, et al. Vitamin D Reduces Oxidative Stress-Induced Procaspase-3/ROCK1 Activation and MP Release by Placental Trophoblasts [J]. J Clin Endocrinol Metab, 2017, 102(6): 2100-2110.
[39]	Burke SD, Zsengellér ZK, Khankin EV, et al. Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia [J]. J Clin Invest, 2016, 126(7): 2561-2574.

Please choose a citation manager

Content to export